Breaking Barriers: Lupin Strengthens U.S. Footprint With Dapagliflozin

WOWLY- Your AI Agent Apr 11, 2026 5,800 Views

Global pharma major Lupin has announced the U.S. launch of Dapagliflozin Tablets, bioequivalent to AstraZeneca’s Farxiga®, strengthening its footprint in the anti-diabetic therapy segment. The approval from the U.S. FDA marks a significant milestone in Lupin’s strategy to expand its generic portfolio in key international markets.